Co-Diagnostics Expands South Asian Reach, Targets $13B Market
March 20, 2026 — Co-Diagnostics' joint venture expands into Bangladesh, Pakistan, Nepal & Sri Lanka, targeting a $13B market for its PCR Pro point-of-care platform & SARAGENE diagnostics.
Curated Health Wellness News
NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
Young Adult Blood Pressure Linked to Heart, Kidney Disease Risk After 40
March 20, 2026 — Study of 300,000 adults finds elevated blood pressure in 30s-40s increases heart and kidney disease risk after 40. Early monitoring crucial for long-term health.
Soligenix's SGX945 Gets UK PIM Designation for Behçet's Disease
March 20, 2026 — Soligenix receives UK Promising Innovative Medicine designation for SGX945 to treat Behçet's disease, strengthening rare disease pipeline with regulatory recognition from MHRA.
Oncolytic Virus Therapy Poised to Revolutionize Cancer Treatment
March 20, 2026 — Calidi Biotherapeutics advances oncolytic virus therapy, a new cancer treatment using viruses to destroy tumors. BioMedWire reports on this transformative biomedical innovation.
LIXTE's LB-100 Compound May Boost Cancer Treatment Effectiveness
March 20, 2026 — LIXTE Biotechnology's LB-100 compound may enhance cancer treatment effectiveness by increasing tumor sensitivity to chemotherapy/radiation and boosting immune response. Learn about this promising oncology development.
Vesicor Appoints Biotech Veteran as CEO Ahead of Key Trials and SPAC Merger
March 20, 2026 — Black Hawk Acquisition's target, Vesicor Therapeutics, appoints Dr. Michael Tolentino as CEO to lead its p53-based cancer drug platform toward FDA trials and a SPAC merger.
Catalyst Crew Seeks FINRA Approval to Rebrand as LataMed AI Corp.
March 20, 2026 — Catalyst Crew Technologies submits to FINRA to change name to LataMed AI Corp., reflecting its shift to AI healthcare tech focused on Latin America, with no change to capital structure.
MEDICLIN Announces 2026 Virtual Press Conference on 2025 Financial Results
March 19, 2026 — MEDICLIN AG invites stakeholders to its 2026 virtual press conference on March 27 to discuss 2025 financial results, outlook, and developments in German healthcare.
Soligenix's HyBryte™ Gains Peer-Reviewed Backing for CTCL Treatment
March 19, 2026 — Soligenix's HyBryte™ for cutaneous T-cell lymphoma gains peer-reviewed support in Expert Opinion on Investigational Drugs, highlighting safety and efficacy ahead of Phase 3 trial analysis in 2026.
Greensboro's Top Orthodontists Transform Smiles with Advanced Care
March 19, 2026 — Davis & Goldberg Orthodontics offers premier braces and Invisalign treatments in Greensboro, NC. Their advanced technology and personalized care help patients achieve confident, healthy smiles.
Dover's Sleep Apnea Solution: Seacoast Braces Offers Personalized Care
March 19, 2026 — Seacoast Braces in Dover, NH offers personalized sleep apnea treatment with oral appliances and advanced care. Learn how their holistic approach improves sleep and health for local residents.
Study: Less Sitting, More Movement Cuts Pregnancy Hypertension Risk by 30%
March 19, 2026 — New research shows pregnant women can reduce hypertension risk by 30% with less sitting and more light activity. Study presented at American Heart Association meeting offers practical pregnancy health guidance.
Aditxt Appoints Jeff Busch as CEO of Ignite Proteomics to Drive Precision Oncology Growth
March 19, 2026 — Aditxt appoints Jeff Busch as CEO of Ignite Proteomics to lead commercial expansion of precision oncology platform using functional protein profiling to guide cancer therapy selection.
Annovis Bio Partners with NeuroRPM to Revolutionize Parkinson's Research with AI
March 19, 2026 — Annovis Bio partners with NeuroRPM to implement AI-powered monitoring in Parkinson's disease trials, using wearable tech to track symptoms and enhance evaluation of buntanetap treatment.
Soligenix's HyBryte Shows Promise for Rare Lymphoma in Key Publication
March 19, 2026 — Soligenix announces HyBryte clinical summary published, highlighting safety and efficacy for cutaneous T-cell lymphoma. Phase 3 trial advances with 2026 analysis expected.
Aclarion Adopts 'Poison Pill' to Shield Shareholders and Tech Innovation
March 19, 2026 — Aclarion adopts a one-year stockholder rights plan to protect against hostile takeovers, ensuring fair value for investors and stability for its Nociscan healthcare technology platform.
Soligenix CEO Touts Positive HyBryte™ Data, Eyes Transformational CTCL Milestone
March 19, 2026 — Soligenix CEO discusses promising Phase 3 data for HyBryte™ in cutaneous T-cell lymphoma, highlighting strong response rates and upcoming milestones in BioMedWire feature.
Aclarion Advances Chronic Back Pain Tech with 2026 Clinical & Reimbursement Goals
March 19, 2026 — Aclarion updates on Nociscan platform for chronic back pain, targeting 2026 clinical trial results & US insurance reimbursement to expand adoption of its AI-driven diagnostic technology.
Catalyst Crew Launches AI Healthcare Platform for Emerging Markets
March 19, 2026 — Catalyst Crew Technologies announces AI Healthcare Platform for emerging markets, designed to analyze patient data, identify clinical risks, and improve care coordination in Latin America.
Florida Eye Bank Receives $228K Grant to Expand Sight-Restoring Care
March 18, 2026 — Florida eye bank Beauty of Sight receives $228,641 grant from Lions Clubs International Foundation to expand laboratory capabilities and increase access to sight-restoring care for patients across the state.